Bronkovent

Quick links to important sections

Bronkovent

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bronkovent

Quick Facts

Property Description
Active Ingredients Salbutamol, Bromhexine, Guaifenesin
Form Syrup or Oral Solution
Pharmacological Class Bronchodilator / Expectorant / Mucolytic
Common Use Improving airflow and clearing mucus
Origin Synthetic / Semi-synthetic Combination

What is Bronkovent and What Type of Drug Is It?

Bronkovent is a multi-action respiratory medication classified as a fixed-dose combination product that addresses both airway constriction and heavy mucus congestion. This medicine incorporates three primary pharmacological actions, containing a Bronchodilator, an Expectorant, and a Mucolytic agent. This particular combination is clinically recognized for supporting patients who experience both difficulty breathing due to tightened airways and significant mucus buildup.

What Ingredients are in Bronkovent and What is its Form?

The core of Bronkovent is the combination of its three active components: Salbutamol (or Albuterol), Bromhexine, and Guaifenesin. The medication is typically manufactured as a Syrup or an Oral Solution, suitable for Oral Route of Administration, which may be preferred by patients who have difficulty using inhalers. The finished product is a manufactured combination product consisting of synthetic and semi-synthetic compounds dissolved in an aqueous base.

Salbutamol is a recognized bronchodilator for managing respiratory obstruction. This establishes that the drug contains a well-recognized component for opening airways.

What is the General Purpose of Bronkovent?

The general purpose of Bronkovent is to relieve the feeling of chest tightness and congestion by improving airflow and helping to clear phlegm. It is often used in scenarios where a patient's discomfort stems from a cough that is both tight and produces excessive, thick mucus. The dual action provides effective symptomatic relief for general respiratory discomfort associated with both narrowed airways and accumulated secretions, facilitating clearer, easier breathing.

Regulatory References

  1. The World Health Organization recognizes Salbutamol as an essential bronchodilator for managing respiratory obstruction

What side effects are possible with Bronkovent?

Possible side effects and safety information

The safety profile for this combination medicine, which contains Salbutamol, Bromhexine, and Guaifenesin, is documented through official government regulatory sources. Adverse reactions are classified by frequency and grouped according to the system or organ they affect.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions Listed in Regulatory Documents
Common Fine tremor, headache (often more frequent at the start of treatment)
Uncommon Palpitations, muscle cramps, nausea, vomiting, diarrhea, dizziness
Rare Hypersensitivity reactions, hypokalaemia, cardiac arrhythmias

The officially listed adverse effects involve the Nervous System (e.g., tremor), the Cardiovascular System (e.g., palpitations, tachycardia), the Gastrointestinal System, and the Immune System.

Documented Serious Safety Considerations

Regulatory documentation highlights the possibility of Serious Adverse Reactions. These include severe, immediate hypersensitivity reactions (such as anaphylaxis and collapse) and a condition known as paradoxical bronchospasm, which is a sudden and life-threatening worsening of breathing. Additionally, severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), have been associated with the Bromhexine component. A potentially significant decrease in serum potassium levels, known as hypokalaemia, is also listed.

Safety Constraints and Special Populations

Caution is advised when this medicine is used in patients with certain pre-existing conditions, including hypertension, cardiac disease, or diabetes mellitus, due to the potential systemic effects of the bronchodilator component. Patients with severe acute asthma are specifically cited as being at an increased risk of developing hypokalaemia. The medicine is formally contraindicated in individuals with known hypersensitivity to any of its active components.

Overdose and Emergency Response

Overdose: When to Seek Emergency Help

Bronkovent (a presumptive name for an adrenergic bronchodilator) overdose is a life-threatening medical emergency that requires immediate attention. Overdose occurs when a person takes more than the recommended amount of the medication, which can happen accidentally or intentionally. Excessive use of inhaled sympathomimetic drugs, the class to which this medication belongs, has been associated with severe complications and fatalities.

Call 911 or the Poison Help Line (1-800-222-1222) immediately if an overdose is suspected.

Overdose Manifestations
Cardiovascular Effects: Severe, rapid heartbeat (tachycardia) that may reach up to 200 beats per minute, heart rhythm irregularities (arrhythmias), high blood pressure followed by low blood pressure, or chest pain.
Neurological/Systemic Effects: Tremors, severe nervousness, headache, dizziness, dry mouth, nausea, vomiting, confusion, convulsions (seizures), or coma.
Metabolic Changes: Low potassium levels (hypokalemia) and high blood sugar levels (hyperglycemia).

Upon arrival, emergency medical staff will monitor vital signs (pulse, blood pressure, breathing) and provide supportive care. Treatment interventions may include the administration of activated charcoal to limit drug absorption, intravenous fluids, and close monitoring of heart rhythm and blood chemistry. The time between exposure and seeking help can be critical for recovery.

Therapeutic Uses of Bronkovent

What Bronkovent Treats: Main Uses and Benefits

Bronkovent is a combination therapy used for symptomatic relief in respiratory conditions that cause both constricted airways and mucus buildup. Its use is aimed at providing supportive therapeutic benefit during periods of heightened symptoms.

The medication is commonly applied in clinical settings that involve acute or unstable symptom patterns, such as asthma, chronic bronchitis, and emphysema. It is relevant for easing symptoms linked to heightened physiological activity, specifically the wheezing and uncomfortable chest tightness that result from constricted airways, alongside managing the presence of thick, tenacious phlegm that is difficult to clear.

“It is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.”

The support provided contributes to improved airflow and assists patients in coping more steadily with symptom fluctuations, helping to ease the overall symptom burden and contribute to improved day-to-day comfort.


Quick Fact: Support for Bronchopulmonary Symptoms

Aspect Symptom Domain
Airflow Support Wheezing, Chest Tightness
Mucus Support Thick, Tenacious Phlegm, Congestion
Conditions Asthma, Chronic Bronchitis, COPD
Patient Benefit Supports general well-being during symptomatic phases

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The use of Bronkovent (Salbutamol, Bromhexine, Guaifenesin) is determined by specific regulatory criteria detailing approved, restricted, and prohibited populations.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for individuals with known hypersensitivity to any of the active ingredients, or in patients diagnosed with thyrotoxicosis, peptic ulcer disease, or unspecified hypertension.

Restricted and Conditional Use

Use is not recommended in pregnant women and nursing (lactating) mothers. Caution is required in patients with severe kidney impairment, severe liver impairment, diabetes mellitus, and certain cardiovascular disorders (e.g., arrhythmias, coronary insufficiency). Caution is also advised for patients with hyperthyroidism or a history of peptic ulceration.

Age-Group Eligibility

The product is generally approved for use in adults and children over the age of two years. However, safety and effectiveness in children under the age of two years have not yet been adequately demonstrated by regulatory authorities.

What should I know about interactions with other medicines?

Bronkovent is a combination product whose interaction profile is defined by its active components, Salbutamol, Bromhexine, and Guaifenesin, as documented in regulatory information. The most critical restrictions involve formal prohibitions against co-administration with certain substance classes. Non-selective Beta-blocking drugs, such as Propranolol, should not usually be prescribed concurrently due to the risk of antagonism of the bronchodilating effect and the potential to induce severe bronchospasm. Similarly, co-use with Monoamine Oxidase Inhibitors (MAOIs) or other sympathomimetic bronchodilators is restricted due to the documented potential for vascular system potentiation.

A key pharmacodynamic interaction involves the additive risk of hypokalemia (low serum potassium). This risk is increased when Bronkovent is co-administered with other medications known to affect potassium levels, including Corticosteroids, Diuretics, or Xanthines (e.g., Theophylline). This interaction may also lead to an increased susceptibility to cardiac arrhythmias if co-used with Digitalis Glycosides (Digoxin).

Furthermore, the Bromhexine component has a documented interaction where it modifies the distribution of certain antibiotics, resulting in an increase of their concentration in the bronchopulmonary secretions. Regulatory notes also indicate that the clearance of Bromhexine or its metabolites may be reduced in patients with Severe Hepatic or Renal Impairment.

Mechanism of Action

️ Modulation of Airway Smooth Muscle Tone (beta2-Adrenoceptor Activation)

This domain explains the action of Salbutamol, which functions as a selective beta2-adrenoceptor agonist on the smooth muscle lining the airways. This interaction initiates a molecular cascade that increases intracellular cAMP levels, ultimately leading to the relaxation of muscle tone. The resulting physiological effect is a reduction in airway resistance through the widening of the air passages.


Dual-Action Mucus Rheology Modulation (Secretolytic and Expectorant)

This domain covers the complementary mechanisms of Bromhexine and Guaifenesin, which alter the physical properties of respiratory secretions. Bromhexine acts secretolytically by increasing enzyme activity to depolymerize the long chemical fibers in the mucus, reducing its stickiness. Guaifenesin uses the Gastro-Pulmonary Vagal Reflex to stimulate bronchial glands, increasing the volume and hydration of airway fluid. The combined physiological consequence is a reduction in mucus viscosity, supporting mucociliary transport function.


Mechanistic Synergy in Addressing Dual Airway Obstruction

The drug's mechanism involves mechanistic synergy where muscle relaxation and mucus preparation occur simultaneously. By addressing both the dynamic obstruction (muscle contraction) and the static obstruction (hyperviscous mucus) at the same time, the combination of effects facilitates the transport of the newly thinned and mobilized secretions through the widened airways.

Dosage and Administration Information

Bronkovent is used as an Oral Solution or Syrup, establishing the single intended route for administration. The medicine is typically designated for short-term use during acute symptomatic phases, and its treatment protocol is structured around a precise, scheduled dosing that applies across all labeled populations.

The general frequency of administration for this combination product is thrice daily (TID), meaning doses should be scheduled three times throughout the day. The required volume is measured in milliliters (mL) and must be determined accurately using a dedicated measuring cup or device. The solution is generally taken after meals to optimize the conditions of intake.

Standard Single Dose Regimens

The specific labeled dosing volume varies by age, but the standard thrice-daily frequency remains constant:

Population Standard Single Dose Volume
Adults 10 mL to 20 mL
Children (6–12 years) 10 mL
Children (under 6 years) 5 mL to 10 mL

The procedural use of the drug requires the volume to be confirmed before ingestion. Furthermore, the administration protocol includes a specific provision for careful consideration when treating subjects with severe renal or hepatic impairment, linking dose assessment to underlying health status. This regimen defines the protocol for delivering the correct volume at the mandated interval.

Recent Clinical Evidence

Research evidence / Overview of studies for Bronkovent

Evidence for use in Acute Respiratory Symptoms

Research has explored the use of the Bronkovent combination in people experiencing acute episodes characterized by both tightened airways and heavy, productive cough. These studies were mainly short-term Randomized Controlled Trials (RCTs) that was studied for comparison to similar medications containing only two active components.

These studies were used in research exploring how symptoms change over time, monitoring metrics such as changes in the quality and volume of mucus, as well as scores tracking the frequency and severity of cough. Findings describe patterns observed in the studies over short durations, often spanning seven days, regarding the measured changes in these symptoms. The evidence gathered from these trials focuses on a very short period of time, and long-term effects are not fully established.

Evidence for use in Chronic Respiratory Conditions

Research has explored whether this combination is relevant in evidence describing how symptoms are measured in conditions involving periods of heightened symptoms, such as Stable Chronic Bronchitis or Acute Exacerbations of COPD (AECOPD). The evidence is largely derived from studies on its individual mucolytic and expectorant components, including Meta-analyses of RCTs and Real World Evidence (RWE).

These studies monitored patient-reported outcomes describing perceived discomfort and scores reflecting daily functioning. Research focused on the mucolytic component in AECOPD described measured changes in criteria used to define treatment completion. However, there is limited information from high-quality trials for the fixed triple-combination in managing chronic, stable conditions. Findings were mixed regarding the component's ability to influence outcomes related to functional limitations, such as the future risk of exacerbations.

Research on Bronchodilator Use in Non-Obstructive Cough

Research was also studied for the use of the bronchodilator component in patients presenting with acute cough but who do not have clinical evidence of underlying airflow limitation. Systematic Reviews of existing trials that examined measurements of daily cough scores showed that there appears to be little measured change in symptoms in this specific population. For non-obstructive cough, the evidence is limited, and certainty remains low for this context.

Evidence in Special Populations

Research describes the combination was studied for use in a broad age range, including both adult and pediatric populations (e.g., from age three). However, the number of individuals within certain age groups, such as the elderly or young children, was often modest. Data for certain groups remain insufficient, particularly concerning individuals with specific comorbidities or populations such as pregnant or breastfeeding individuals.

What is Still Uncertain About the Research

Comparative evidence is lacking for the triple-combination against standard single-agent treatments or against a placebo. Evidence quality varies across studies, particularly when reviewing the long-term impact on chronic diseases or the findings related to the bronchodilator component. Research does not determine whether an individual will respond similarly to the group patterns observed in studies, and long-term effects are not fully established.

Key Studies & References

  1. DrugBank: Salbutamol/Bromhexine/Guaifenesin (Combination Profile)

Frequently Asked Questions (FAQ)

Common questions about Bronkovent (FAQ)


Q: Are there any long-term health concerns associated with using Bronkovent?

A: Official product information describes Bronkovent as a treatment typically designated for short-term use during acute symptoms. Regulatory research overviews state that the long-term effects of the fixed triple combination product have not yet been fully established in studies.

Q: Is it normal to feel shaky or nervous after taking Bronkovent?

A: Official safety information documents that feeling shaky, clinically described as a fine tremor, is a commonly reported side effect. The bronchodilator component can also lead to other central nervous system effects like restlessness or feeling hyperactive.

Q: Can Bronkovent affect blood pressure levels?

A: Regulatory labeling advises caution because the medicine may affect blood pressure levels, particularly in susceptible patients. Its use is specifically restricted or requires careful monitoring for people who have pre-existing high blood pressure (hypertension).

Q: What are the signs of a severe allergic reaction to Bronkovent?

A: Severe allergic reactions (hypersensitivity) are documented in official safety information. Signs can include swelling of the face, lips, or throat (angioedema), widespread rash (urticaria), a sudden worsening of breathing, and a rapid, serious drop in blood pressure (collapse).

Q: Are there any specific foods or drinks I should avoid while using Bronkovent?

A: Official administration guidance suggests that the syrup may be taken after meals as part of its structured protocol. Regulatory documents generally focus on specific drug-to-drug interactions. Patients should check with a healthcare provider regarding any specific dietary concerns, as drug labels may not list restrictions for common foods or non-alcoholic drinks.

Q: Are there any official Boxed Warnings or special cautions for Bronkovent?

A: Regulatory documents include detailed warnings regarding potential serious adverse reactions. These warnings describe life-threatening events such as sudden worsening of breathing (paradoxical bronchospasm) and rare, severe skin conditions (SCARs).

Q: Are there any ongoing clinical trials for Bronkovent I should know about?

A: Information about ongoing clinical trials is collected in official government and international registries. These resources contain information on current research concerning the triple combination and its individual active ingredients.

Q: Is Bronkovent considered a steroid medication?

A: No, Bronkovent is not classified as a steroid. According to official pharmacological descriptions, its active ingredients function as a bronchodilator (to relax airway muscles), a mucolytic, and an expectorant (to clear mucus).

Q: How quickly does Bronkovent usually start working?

A: Official product information states that the bronchodilator component is short-acting and begins to work quickly. The onset of action is typically noted to occur within minutes after taking the solution.

Q: How long does the effect of a single dose of Bronkovent last?

A: Regulatory documents indicate that the effect of the bronchodilator component has a duration of action of approximately four to six hours in most patients. The scheduled dosing protocol is based on this established duration.

Q: Can Bronkovent cause sleep problems or insomnia?

A: Official adverse reaction reports for the active components sometimes include potential central nervous system effects such as restlessness or insomnia (difficulty sleeping). These effects are generally due to the systemic action of the bronchodilator ingredient.

Q: Does using Bronkovent frequently reduce its effectiveness over time?

A: Official regulatory warnings advise that if the usual relief from the medication seems diminished or requires more frequent use, this may signal a worsening of the underlying condition. Regulatory guidance indicates that dosage adjustments should only be made by a healthcare provider.

Q: Does Bronkovent interact with over-the-counter cold and flu medicines?

A: Official interaction warnings restrict the use of Bronkovent with certain medications, including other sympathomimetic bronchodilators (which may be found in some cold and flu remedies). Official guidance notes the importance of discussing all over-the-counter cold or cough medicines with a healthcare professional.

Q: Is it safe to drink alcohol while taking Bronkovent?

A: Official patient counseling often notes the need for general caution regarding the concurrent use of alcohol with this medicine. Alcohol consumption may potentially intensify certain side effects of the medication, such as dizziness.

Q: Does Bronkovent interact with common pain relievers like ibuprofen?

A: Common over-the-counter pain relievers such as Ibuprofen are generally not listed as major interaction restrictions in regulatory documents. Official safety guidance stresses the importance of informing a healthcare provider about all medications and supplements being used.

Q: Where can I find the official FDA patient information leaflet for Bronkovent?

A: The official Prescribing Information and patient guidance are published by regulatory bodies like the FDA. This information can be located on governmental websites and portals, such as the FDA's DailyMed database.

Q: What happens if I accidentally miss a scheduled dose of Bronkovent?

A: Official patient information advises that if a dose is missed, it should be taken as soon as the patient remembers, unless it is very close to the time for the next scheduled dose. Regulatory guidance states that a double dose should not be taken to make up for a missed dose.

Q: What is the guidance if I accidentally use more Bronkovent than recommended?

A: In the event of using more than the recommended volume (overdose), regulatory documents define this as a medical emergency requiring immediate attention. Overdose symptoms can include rapid or irregular heartbeat (tachycardia) and very low potassium levels (hypokalemia).

Q: Does Bronkovent cause dry mouth or throat irritation?

A: Yes, official safety information for related combination products lists dry mouth or throat irritation as potential adverse reactions.

Q: Is there a generic version of Bronkovent available?

A: Regulatory databases in various countries list products containing the same triple combination of active ingredients under different brand names. These alternative products are often considered therapeutically equivalent.

Q: Is Bronkovent known to be addictive or habit-forming?

A: The active ingredients are not typically classified as controlled substances by regulatory bodies. Therefore, the official product labeling does not contain warnings regarding the potential for addiction or habit-forming use.

Q: Is Bronkovent associated with weight gain or changes in appetite?

A: Official adverse reaction reports do not typically list weight gain as a common side effect. However, other changes affecting intake, such as decreased appetite or nausea, are sometimes reported in the official documents for the active components.

Q: Why is Bronkovent available by prescription only?

A: The medicine is available only by prescription because its use requires the expertise of a licensed physician for proper patient selection and diagnosis. Prescription status also ensures that patients are monitored for potential serious side effects, such as low potassium levels (hypokalemia).

How should Bronkovent be stored and disposed of?

Storage and Disposal Requirements for Bronkovent Syrup

Bronkovent (Salbutamol, Bromhexine, Guaifenesin Syrup) must be stored and handled according to the instructions on the official regulatory label to preserve its stability.

Labeled Storage Conditions

The syrup must be stored below 30 C and should be protected from light. It is essential that the medicine is not frozen. The product has a labeled shelf life of up to 36 months when stored under these conditions.

Handling and Disposal

The product must be kept out of the sight and reach of children as a critical safety requirement. When disposing of unused or expired syrup, do not pour it down the sink or flush it. Instead, follow local regulations, which often advise utilizing drug take-back programs or mixing the medicine with an undesirable substance for household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Bronkovent found in:

A-Z Index: